{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:47:38Z","timestamp":1794278858442,"version":"4.9.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014476","name":"Pfizer Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ijantimicag.2023.106867","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T21:09:02Z","timestamp":1685048942000},"page":"106867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["In vitro activities of ceftazidime\u2013avibactam, ceftolozane\u2013tazobactam, meropenem\u2013vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012\u20132021"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6346-082X","authenticated-orcid":false,"given":"Yu-Lin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chien","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ren","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106867_bib0001","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13756-022-01187-8","article-title":"Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients","volume":"11","author":"Gill","year":"2022","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0002","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13756-018-0370-9","article-title":"Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis","volume":"7","author":"Raman","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0003","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1590\/s1678-9946202163071","article-title":"Carbapenem-resistant Pseudomonas aeruginosa strains: a worrying health problem in intensive care units","volume":"63","author":"Souza","year":"2021","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02000-21","article-title":"Geographic patterns of carbapenem-resistant Pseudomonas aeruginosa in the Asia-Pacific region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2015\u20132019","volume":"66","author":"Lee","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0005","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3390\/pathogens10101310","article-title":"Bacterial antibiotic resistance: The most critical pathogens","volume":"10","author":"Mancuso","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0006","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3201\/eid2507.181200","article-title":"Carbapenem-resistant Pseudomonas aeruginosa at US emerging infections program sites, 2015","volume":"25","author":"Walters","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0007","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4103\/ijccm.IJCCM_341_17","article-title":"Assessment of doripenem, meropenem, and imipenem against respiratory isolates of Pseudomonas aeroginosa in a tertiary care hospital of North India","volume":"21","author":"Negi","year":"2017","journal-title":"Indian J Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0008","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jmii.2022.02.001","article-title":"Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms","volume":"55","author":"Sy","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0009","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.medin.2022.02.004","article-title":"Resistance mechanisms in Gram-negative bacteria","volume":"46","author":"Lepe","year":"2022","journal-title":"Med Intensiva (Engl Ed)"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00284-022-03061-7","article-title":"Current treatment strategies against multidrug-resistant bacteria: a review","volume":"79","author":"Parmanik","year":"2022","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0011","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/jac\/dkr232","article-title":"Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem","volume":"66","author":"Riera","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0012","series-title":"Performance standards for antimicrobial susceptibility testing: 32th informational supplement M100-S32","year":"2022"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0013","unstructured":"Cefoperazone-sulbactam package inset. Available at https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=14800. 2009. [accessed October 2022]."},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0014","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0. Available at: http:\/\/www.eucast.org [accessed October 2022]."},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0015","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0016","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jmii.2021.07.015","article-title":"Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018","volume":"55","author":"Jean","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0017","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jmii.2019.08.017","article-title":"Changes in the resistance and epidemiological characteristics of Pseudomonas aeruginosa during a ten-year period","volume":"54","author":"Feng","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106679","volume":"60","author":"Lee","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0019","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijid.2022.12.010","article-title":"Geographic patterns of Acinetobacter baumannii and carbapenem resistance in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012\u20132019","volume":"127","author":"Lee","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0020","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1086\/599811","article-title":"In vitro activity of doripenem","volume":"49","author":"Sahm","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0021","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: past, present, and future","volume":"55","author":"Papp-Wallace","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0022","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/14787210.5.5.793","article-title":"Carbapenems in the USA: focus on doripenem","volume":"5","author":"Lister","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0023","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/jac\/dku048","article-title":"Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries","volume":"69","author":"Castanheira","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0024","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ijantimicag.2013.02.001","volume":"41","author":"Jean","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0025","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/ja.2015.25","article-title":"Antimicrobial resistance surveillance of doripenem in China","volume":"68","author":"Li","year":"2015","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.614058","article-title":"Mobile carbapenemase genes in Pseudomonas aeruginosa","volume":"12","author":"Yoon","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0027","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/antibiotics11091212","article-title":"Carbapenem combinations for infections caused by carbapenemase-producing Pseudomonas aeruginosa: experimental in vitro and in vivo analysis","volume":"11","author":"Herrera-Espejo","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0028","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/jac\/dkac084","article-title":"Resistance mechanisms and molecular epidemiology of Pseudomonas aeruginosa isolates from patients with bronchiectasis","volume":"77","author":"Cabrera","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00496-22","article-title":"Whole-genome sequencing reveals diversity of carbapenem-resistant Pseudomonas aeruginosa collected through CDC's emerging infections program, United States, 2016\u20132018","volume":"66","author":"Stanton","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0030","article-title":"Antibiotic resistance in Pseudomonas aeruginosa and adaptation to complex dynamic environments","volume":"6","author":"Sommer","year":"2020","journal-title":"Microb Genom"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0031","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jmii.2021.11.009","article-title":"Molecular detection of respiratory pathogens in community-acquired pneumonia involving adults","volume":"55","author":"Lin","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0032","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12941-016-0127-3","article-title":"Characterization of Pseudomonas aeruginosa with discrepant carbapenem susceptibility profile","volume":"15","author":"Pragasam","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0033","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","article-title":"Carbapenemase-producing Pseudomonas aeruginosa \u2013 an emerging challenge","volume":"11","author":"Tenover","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0034","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3390\/ijerph18031003","article-title":"Reduction of multidrug-resistant (MDR) bacterial infections during the COVID-19 pandemic: a retrospective study","volume":"18","author":"Bentivegna","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0036","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s10096-021-04308-0","article-title":"The ERACE-PA global surveillance program: ceftolozane\/tazobactam and ceftazidime\/avibactam in vitro activity against a global collection of carbapenem-resistant Pseudomonas aeruginosa","volume":"40","author":"Gill","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0037","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0038","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijid.2021.10.022","article-title":"Antimicrobial activities of ceftazidime\/avibactam, ceftolozane\/tazobactam, imipenem\/relebactam, meropenem\/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections","volume":"113","author":"Sader","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0039","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jmii.2021.08.012","volume":"55","author":"Liu","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106867_bib0040","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/14787210.2022.2071701","article-title":"Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol","volume":"20","author":"Canton","year":"2022","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:45:29Z","timestamp":1760377529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923001462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0924857923001462"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106867","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activities of ceftazidime\u2013avibactam, ceftolozane\u2013tazobactam, meropenem\u2013vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012\u20132021","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106867","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106867"}}